252 results
8-K
EX-3.1
DMKPQ
DMK Pharmaceuticals Corp
23 Jan 24
Material Modifications to Rights of Security Holders
5:22pm
at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly
8-K
EX-99.1
DMKPQ
DMK Pharmaceuticals Corp
3 Jan 24
Regulation FD Disclosure
5:00pm
transdermal system for treatment opioid use disorder US market$3B addressed by old Rx solutions with limitations of access, efficacy, and safety o NIH … - sponsored studies show equal efficacy to treat withdrawal symptoms, with improved safety observed in pre - clinical studies Opportunity to expand
8-K
EX-10.1
DMKPQ
DMK Pharmaceuticals Corp
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
Act; the Americans with Disabilities Act Amendments Act of 2008; the Family and Medical Leave Act of 1993; the Occupational Safety and Health Act … with the Equal Employment Opportunity Commission, the Occupational Safety and Health Review Commission (“OSH”), the National Labor Relations Board
8-K
EX-10.2
el30 g4md3k2rvag0vd
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
DEFC14A
b7h5hrlpngyhajnf
12 Oct 23
Proxy in contested solicitation
4:22pm
PREC14A
fu3pm3jh7
2 Oct 23
Preliminary proxy with contested solicitation
4:49pm
8-K
EX-3.2
t35rq7zlh 57
8 Sep 23
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
4:50pm
8-K
EX-99.1
h7cejhfi8vi495
8 Sep 23
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
4:50pm
8-K
EX-10.1
wcg y4txlu040v
29 Aug 23
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
xpbg4f
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
424B4
9pnyt
3 Aug 23
Prospectus supplement with pricing info
4:55pm
FWP
ax4 a98b52s
27 Jul 23
Free writing prospectus
6:08am
8-K
u2fskx8khjjwwkyx40
26 May 23
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
4:25pm